Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Solid Tumors
Interventions: Linifanib, Rifampin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Tucson, Arizona • Madison, Wisconsin

Conditions: Advanced Cancers
Interventions: Pazopanib, Lapatinib, Trastuzumab (Herceptin®); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours
Interventions: 177Lu-3BP-227 (also called 177Lu-IPN01087); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors, Malignant Neoplasm
Interventions: MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more

Conditions: Locally Advanced Malignant Neoplasm, Metastatic Cancer
Interventions: OMP-336B11; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ganitumab, laboratory biomarker analysis, pharmacological study, biopsy; Biological · Other · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer
Interventions: MEDI-573; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation, MEK Alteration, MAP2K1 Gene Mutation, MAP2K1 Gene Alteration, MAP2K2 Gene Mutation, MAP2K2 Gene Alteration
Interventions: Ulixertinib, Physician's Choice; Drug
Lead sponsor: BioMed Valley Discoveries, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more

Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions: REGN10597, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more

Conditions: Metastatic Solid Tumors
Interventions: Elesclomol Sodium; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Rochester, Maryland • San Antonio, Texas • Madison, Wisconsin

Conditions: Solid Tumor
Interventions: BS006 Injection; Drug
Lead sponsor: Binhui Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Detroit, Michigan

Conditions: Neoplasms
Interventions: NM-3; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: ST101, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Sapience Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more

Conditions: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions: Acasunlimab, Pembrolizumab, Docetaxel; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more

Conditions: Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
Interventions: Bosutinib, Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Advanced Solid Tumors
Interventions: U3-1287 (AMG888); Drug
Lead sponsor: U3 Pharma GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: Rebastinib, Carboplatin; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more

Conditions: Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions: P-MUC1C-ALLO1 CAR-T cells, Rimiducid; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2039
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 11 more

Conditions: Advanced Solid Tumors, HER2 Mutation
Interventions: BAY2927088; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more

Conditions: Cancer, Solid Tumors
Interventions: CBP501 and Cisplatin; Drug
Lead sponsor: CanBas Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Las Vegas, Nevada

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Interventions: PD-L1 t-haNK; Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Advanced MTAP-null Solid Tumors
Interventions: Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Oxnard, California + 24 more

Conditions: Cancer, Neoplasm
Interventions: SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Aurora, Colorado + 6 more

Conditions: Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
Interventions: CB-839, Capecitabine; Drug
Lead sponsor: David Bajor, MD; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer